Experts: Cuts at FDA could jeopardize US standing in clinical research, product innovation
Regulatory NewsJoanne S. Eglovitch
Approval/marketing authorizationBiotechnologyClinical TrialsMedical DevicesPharmaceuticalsProduct LifecyclePublic healthRegulatory strategyResearch, Design and DevelopmentUnited StatesUS Food and Drug Administration (FDA)User fees